
Absci Corp
ABSIHealthcare|Biotechnology|USA
$10.60
-0.87 (-7.59%)
Tangible Book
$0.85
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
7.19,
22.22,
49.09,
55.77,
104.95
],
"ebit_estimate": [
-130.04,
-121.28,
-146.83,
-164.41,
-127.63
],
"ebitda_estimate": [
-109.74,
-111.38,
-86.62,
-121.3,
null
],
"net_income_estimate": [
-123.28,
-112.35,
-153.22,
-162.28,
-118.79
],
"per_share_eps_estimate": [
-0.81,
-0.66,
-0.73,
-0.68,
-0.43
],
"eps_nri_estimate": [
-0.8,
-0.68,
-0.73,
-0.68,
-0.43
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
1.31,
1.38,
1.43,
null,
null
],
"pretax_income_estimate": [
-127.89,
-123.03,
-144.31,
-162.28,
-118.79
],
"operating_cash_flow_per_share_estimate": [
-0.68,
-0.6,
null,
null,
null
],
"roa_estimate": [
-57.1,
-66.2,
null,
null,
null
],
"roe_estimate": [
-57.3,
-58.78,
-41.89,
null,
null
],
"gross_margin_estimate": [
100,
100,
100,
100,
null
],
"operating_cash_flow_estimate": [
-104.01,
-91.78,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
0
],
"long_term_growth_rate_mean": 5.74,
"long_term_revenue_growth_rate_mean": "164.34",
"future_per_share_eps_estimate_growth": 6.12,
"future_eps_nri_estimate_growth": 5.74,
"future_revenue_estimate_growth": 164.34,
"future_ebit_estimate_growth": -5.42,
"future_ebitda_estimate_growth": 6.41,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -7.93,
"future_pretax_income_estimate_growth": -6.6,
"future_book_value_per_share_estimate_growth": 4.66,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": 11.08,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712",
"202803"
],
"revenue_estimate": [
1.27,
1.35,
1.6,
1.7,
4.55,
4.5,
4.1,
1.7
],
"ebit_estimate": [
-32.22,
-32.28,
-34.04,
-31.5,
-31.5,
-32,
-32.5,
null
],
"ebitda_estimate": [
-29.65,
-27.65,
-30.45,
-3.9,
-29.9,
-27.2,
-23.4,
-3
],
"net_income_estimate": [
-30.29,
-30.85,
-32.64,
-30.5,
-30.5,
-31,
-31.5,
null
],
"per_share_eps_estimate": [
-0.2,
-0.21,
-0.2,
-0.2,
-0.2,
-0.2,
-0.21,
null
],
"eps_nri_estimate": [
-0.2,
-0.21,
-0.2,
-0.2,
-0.2,
-0.2,
-0.21,
null
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-31.37,
-32.52,
-34.09,
-30.5,
-30.5,
-31,
-31.5,
null
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
100,
100,
100,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null,
null
],
"long_term_growth_rate_mean": 5.74,
"long_term_revenue_growth_rate_mean": "164.34",
"future_per_share_eps_estimate_growth": 6.12,
"future_eps_nri_estimate_growth": 5.74,
"future_revenue_estimate_growth": 164.34,
"future_ebit_estimate_growth": -5.42,
"future_ebitda_estimate_growth": 6.41,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -7.93,
"future_pretax_income_estimate_growth": -6.6,
"future_book_value_per_share_estimate_growth": 4.66,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": 11.08,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}